In Vitro Activities of β-Lactam–β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens | Zendy

Lindsay J. Caverly | Zendy; Theodore Spilker | Zendy; Linda M. Kalikin | Zendy; Terri Stillwell | Zendy; Carol Young | Zendy; David B. Huang | Zendy; John J. LiPuma | Zendy

Open Access

In Vitro Activities of β-Lactam–β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens

Author(s) -

Lindsay J. Caverly,

Theodore Spilker,

Linda M. Kalikin,

Terri Stillwell,

Carol Young,

David B. Huang,

John J. LiPuma

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01595-19

Subject(s) - cystic fibrosis , antimicrobial , microbiology and biotechnology , medicine , in vitro , respiratory system , respiratory disease , lactam , pharmacology , biology , lung , chemistry , biochemistry , stereochemistry

We tested thein vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420Burkholderia ,Achromobacter ,Stenotrophomonas , andPandoraea strains, 89% of which were cultured from respiratory specimens from persons with cystic fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research